 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
REGULAR ARTICLES |
*
Department of Medicine, The University of North Carolina, Chapel Hill,
North Carolina
Department of Internal Medicine, The Ohio State University, Columbus,
Ohio.
Correspondence to Dr. Lee A. Hebert, The Ohio State University, 1654 Upham Dr, Room N210, Columbus, OH 43210. Phone: 614-293-4997; Fax: 614-293-3073; E-mail: hebert.l{at}osu.edu
Abstract. Controlled clinical trials in renal transplantation have demonstrated that mycophenolate mofetil is well tolerated and has lower renal transplant rejection rates than azathioprine regimens. This study reports on the clinical experiences at two institutions with mycophenolate mofetil (MMF) for severe lupus nephritis. Twelve patients with relapsing or resistant nephritis previously treated with cyclophosphamide therapy and one patient who refused cyclophosphamide as initial therapy for diffuse proliferative nephritis but accepted MMF were included. During combined MMF/prednisone therapy, serum creatinine values remained normal or declined from elevated values: mean change in serum creatinine was -0.26 ± 0.46 µM/L, P = 0.039. Proteinuria significantly decreased: mean change in urine protein-to-creatinine ratios was -2.53 ± 3.76, P = 0.039. Decreased serum complement component C3 and elevated anti-double-stranded DNA antibody levels at baseline improved in some, but not all, patients. The mean initial dose of MMF was 0.92 g/d (range, 0.5 to 2 g/d). The mean duration of therapy was 12.9 mo (range, 3 to 24 mo). Adverse events included herpes simplex stomatitis associated with severe leukopenia (n = 1), asymptomatic leukopenia (n = 2), nausea/diarrhea (n = 2), thinning of scalp hair (n = 1), pancreatitis (n = 1), and pneumonia without leukopenia (n = 1). Recurrence of the pancreatitis led to discontinuation of MMF in this patient; all other adverse events resolved with dose reduction. It is concluded that MMF is well tolerated and has possible efficacy in controlling major renal manifestations of systemic lupus erythematosus. Controlled clinical trials are needed to define the role of MMF in the management of lupus nephritis.
This article has been cited by other articles:
 |
|
 |
|
  O Traitanon, Y Avihingsanon, V Kittikovit, N Townamchai, T Kanjanabuch, K Praditpornsilpa, J Wongchinasri, K Tungsanga, and S Eiam-Ong Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study Lupus, August 1, 2008; 17(8): 744 - 751. [Abstract] [PDF]
|
|
|
|
|
|
S Lionaki, P. Kapitsinou, A Iniotaki, A Kostakis, H. Moutsopoulos, and J. Boletis Kidney transplantation in lupus patients: a case-control study from a single centre Lupus, July 1, 2008; 17(7): 670 - 675. [Abstract] [PDF]
|
|
|
|
|
|
W.P. de Castro, J.V. Morales, M.B. Wagner, M. Graudenz, M.I. Edelweiss, and L.F. Goncalves Hypertension and Afro-descendant ethnicity: a bad interaction for lupus nephritis treated with cyclophosphamide? Lupus, September 1, 2007; 16(9): 724 - 730. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Walsh, M. James, D. Jayne, M. Tonelli, B. J. Manns, and B. R. Hemmelgarn Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis Clin. J. Am. Soc. Nephrol., September 1, 2007; 2(5): 968 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zhu, N. Chen, Y. Lin, H. Ren, W. Zhang, W. Wang, X. Pan, and H. Yu Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1933 - 1942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.J. Hunt, S. Tueger, J. Pattison, J. Cavenagh, and D.P. D'Cruz Microangiopathic haemolytic anaemia secondary to lupus nephritis: an important differential diagnosis of thrombotic thrombocytopenic purpura Lupus, May 1, 2007; 16(5): 358 - 362. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]
|
|
|
|
|
|
D. C. Preddie, G. S. Markowitz, J. Radhakrishnan, T. L. Nickolas, V. D. D'Agati, J. A. Schwimmer, M. Gardenswartz, R. Rosen, and G. B. Appel Mycophenolate Mofetil for the Treatment of Interstitial Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 718 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ponticelli New Therapies for Lupus Nephritis Clin. J. Am. Soc. Nephrol., July 1, 2006; 1(4): 863 - 868. [Full Text] [PDF]
|
|
|
|
|
|
M A Dooley Mycophenylate mofetil: what role in the treatment of lupus? Lupus, March 1, 2006; 15(3): 179 - 182. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, D. J. Wallace, M. H. Weisman, et al. Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis. N. Engl. J. Med., November 24, 2005; 353(21): 2219 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Karim, C. N. Pisoni, L. Ferro, M. F. Tungekar, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy Rheumatology, October 1, 2005; 44(10): 1317 - 1321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Guo, J C. Leung, L Y. Chan, S L Lui, A W. Tsang, and K N Lai Modulation of intra-pulmonary TGF-b expression by mycophenolate mofetil in lupus prone MRL/lpr mice Lupus, August 1, 2005; 14(8): 583 - 592. [Abstract] [PDF]
|
|
|
|
|
|
M Thomas, J Blennerhassett, and R Walker Relapse with transformation of lupus nephritis in a transplant kidney Lupus, July 1, 2005; 14(7): 554 - 556. [Abstract] [PDF]
|
|
|
|
 |
|
 D. M. Fine Pharmacological Therapy of Lupus Nephritis JAMA, June 22, 2005; 293(24): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C N Pisoni, Y Karim, and M J Cuadrado Mycophenolate mofetil and systemic lupus erythematosus: an overview Lupus, March 1, 2005; 14(3_suppl): s9 - s11. [Abstract] [PDF]
|
|
|
|
|
|
T M Chan Lupus nephritis: induction therapy Lupus, March 1, 2005; 14(3_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
M Y Karim and I C Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, March 1, 2005; 14(3_suppl): s39 - s41. [Abstract] [PDF]
|
|
|
|
|
|
E M Ginzler and C Aranow Mycophenolate mofetil in lupus nephritis Lupus, January 1, 2005; 14(1): 59 - 64. [Abstract] [PDF]
|
|
|
|
|
|
C. Pisoni, Y. Karim, and M. Cuadrado Mycophenolate mofetil and systemic lupus erythematosus: an overview Lupus, January 1, 2005; 14(1_suppl): s9 - s11. [Abstract] [PDF]
|
|
|
|
|
|
T. Chan Lupus nephritis: induction therapy Lupus, January 1, 2005; 14(1_suppl): s27 - s32. [Abstract] [PDF]
|
|
|
|
|
|
M. Karim and I. Abbs Mycophenolate mofetil in nonlupus glomerulonephropathy Lupus, January 1, 2005; 14(1_suppl): s39 - s41. [Abstract] [PDF]
|
|
|
|
|
|
P I Sidiropoulos and D T Boumpas Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients Lupus, May 1, 2004; 13(5): 391 - 397. [Abstract] [PDF]
|
|
|
|
|
|
P. P. Kapitsinou, J. N. Boletis, F. N. Skopouli, K. A. Boki, and H. M. Moutsopoulos Lupus nephritis: treatment with mycophenolate mofetil Rheumatology, March 1, 2004; 43(3): 377 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ding, M. Zhao, W. Zou, Y. Liu, and H. Wang Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study Lupus, February 1, 2004; 13(2): 113 - 118. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Neumann, M. Haidinger, H. Jager, H. Grutzmacher, A. Griesmacher, M. M. Muller, P. M. Bayer, and F. Thomas Meisl Pharmacokinetics of Mycophenolate Mofetil in Patients with Autoimmune Diseases Compared Renal Transplant Recipients J. Am. Soc. Nephrol., March 1, 2003; 14(3): 721 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Zatz, I. L. Noronha, and C. K. Fujihara Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies Am J Physiol Renal Physiol, December 1, 2002; 283(6): F1167 - F1175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Y. Karim, P. Alba, M.-J. Cuadrado, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents Rheumatology, August 1, 2002; 41(8): 876 - 882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Nieto, E. Escudero, E. Navarro, M. Yanez-Mo, A. Martin, G. Perez de Lema, F. Sanchez-Madrid, and F. Mampaso Effects of Mycophenolate Mofetil in Mercury-Induced Autoimmune Nephritis J. Am. Soc. Nephrol., April 1, 2002; 13(4): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Badid, A. Desmouliere, and M. Laville Mycophenolate mofetil: implications for the treatment of glomerular disease Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1752 - 1756. [Full Text] [PDF]
|
|
|
|
|
|
E J Kingdon, A G McLean, E Psimenou, A Davenport, S H Powis, P Sweny, and A Burns The safety and efficacy of MMF in lupus nephritis: a pilot study Lupus, September 1, 2001; 10(9): 606 - 611. [Abstract] [PDF]
|
|
|
|
 |
|
 G. G. Illei, H. A. Austin III, M. Crane, L. Collins, M. F. Gourley, C. H. Yarboro, E. M. Vaughan, T. Kuroiwa, C. L. Danning, A. D. Steinberg, et al. Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Ann Intern Med, August 21, 2001; 135(4): 248 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Mosca, R Neri, S Giannessi, A Pasquariello, R Puccini, W Bencivelli, and S Bombardieri Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis Lupus, April 1, 2001; 10(4): 253 - 257. [Abstract] [PDF]
|
|
|
|
|
|
K Takada, G G Illei, and D T Boumpas Cyclophosphamide for the treatment of systemic lupus erythematosus Lupus, March 1, 2001; 10(3): 154 - 161. [Abstract] [PDF]
|
|
|
|
|
|
D Adu, J Cross, and D R. Jayne Treatment of systemic lupus erythematosus with mycophenolate mofetil Lupus, March 1, 2001; 10(3): 203 - 208. [Abstract] [PDF]
|
|
|
|
 |
|
 I. Boehm and T. Bieber Chilblain Lupus Erythematosus Hutchinson: Successful Treatment With Mycophenolate Mofetil Arch Dermatol, February 1, 2001; 137(2): 235 - 236. [Full Text] [PDF]
|
|
|
|
|
|
J Cross and D Jayne Mycophenolate mofetil in lupus nephritis Lupus, November 1, 2000; 9(9): 647 - 650. [PDF]
|
|
|
|
|
|
T. M. Chan, F. K. Li, C. S.O. Tang, R. W.S. Wong, G. X. Fang, Y. L. Ji, C. S. Lau, A. K.M. Wong, M. K.L. Tong, K. W. Chan, et al. Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis N. Engl. J. Med., October 19, 2000; 343(16): 1156 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Falk Treatment of Lupus Nephritis -- A Work in Progress N. Engl. J. Med., October 19, 2000; 343(16): 1182 - 1183. [Full Text]
|
|
|
|
|
|
D S Hallegua and D J Wallace How accelerated atherosclerosis in SLE has changed our management of the disorder Lupus, March 1, 2000; 9(3): 228 - 231. [Abstract] [PDF]
|
|
|
|
|
|
M. Gaubitz, A. Schorat, H. Schottel, P. Kern, and W. Domschke Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial Lupus, November 1, 1999; 8(9): 731 - 736. [Abstract] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
